Array Biopharma, Inc. (NASDAQ: ARRY) reported Q4 EPS of ($0.22), $0.01 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $6 million versus the consensus estimate of $8.1 million.

For earnings history and earnings-related data on Array Biopharma, Inc. (ARRY) click here.